About Icosavax
Icosavax is a Healthcare company based in Seattle (United States) founded in 2017 by Adam Simpson, and was acquired by Astrazeneca in December 2023. Icosavax has raised $152 million across 3 funding rounds from investors including Astrazeneca, Citadel and Janus Henderson Investors. The company has 60 employees. Its chief executive, as recorded, is Adam Simpson. Its focus areas include Life Sciences, Pulmonology, Drugs and Lung Infections. Its legal entity is ICOSAVAX, INC. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
- Headquarters Seattle, United States
- Employees 60
- Founders Adam Simpson
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website icosavax.com
- Social LinkedIn X Facebook
- Acquired by Astrazeneca (Dec 2023)
- Legal Name Icosavax, Inc.
- Total Equity Funding$152M (USD)
in 3 rounds
- Latest Funding Round$100M (USD), Series B
Apr 2021
- InvestorsAstrazeneca
& 13 more
- Employee Count60
- Acquired byAstrazeneca
(Dec 2023)
Funding Insights of Icosavax
Icosavax has successfully raised a total of $152M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152M
- Total Rounds 3
- Last Round Series B — $100M
- First Round $52M
(Oct 2019)
- Investors Count 13
All 3 funding rounds of Icosavax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $100M | Series B | – | RA Capital Management | |
| Oct 2020 | $6.5M | Grant | – | – | |
| Oct 2019 | $52M | Series A | – | Qiming |
14 investors in total: 14 institutional.
Investors in Icosavax
Icosavax has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital firm | omegafunds.com | Boston, United States | ||
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Tech startups are invested in by this venture capital firm. | nd.capital | Woodside, United States | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Healthcare companies are funded by Qiming, a venture capital firm. | qimingvcusa.com | Cambridge, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Icosavax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Icosavax
33 people are tracked at Icosavax (13 in leadership, 11 in board & advisors, 9 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
Adam Simpson | Founder & CEO | Leadership |
Niranjan Kanesa-Thasan | Chief Medical Officer | Leadership |
Thalia Nguyen | Director, Technical Operations Project Management | Leadership |
Douglas Holtzman | Chief Scientific Officer | Leadership |
Geremy Knapp | Director Of Quality Control | Leadership |
M. Amin Khan | EVP & Head of R&D | Leadership |
Amin Khan | Executive VP and Head R&D | Leadership |
Andy Castro | Director, Accounting | Leadership |
Adrian DuPre | Sr. Director, Information Technology | Leadership |
Inna Dashevsky | Sr. Director PMO | Leadership |
Kevin DeGiusti | Director of Drug Substance Operations | Leadership |
Peter de Vries | Director, Scientific Project Management, Preclinical | Leadership |
W. Jacob Ezzell | Director of Drug Product Operations | Leadership |
James Wassil | Director | Board & advisors |
Neil King | Chair, Scientific Advisory Board | Board & advisors |
Ann Veneman | Director | Board & advisors |
Heidi Kunz | Director | Board & advisors |
Christian Mandl | SAB Member | Board & advisors |
Mark McDade | Chair | Board & advisors |
David Baker | Co-Founder & Scientific Advisor | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for Icosavax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Icosavax
5 dated milestones of Icosavax across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Icosavax is founded.
- Funding First funding round of $52.0M.
- Funding Latest funding round, Series B, of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Astrazeneca.
Competitors of Icosavax
Icosavax has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Icosavax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Icosavax (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Icosavax
Complete news archive for Icosavax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Icosavax
Icosavax was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Icosavax is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Adam Simpson is the CEO of Icosavax, as recorded in our data. They have also founded this company.
Icosavax is a funded company, having raised a total of $152M across 3 funding rounds to date. The company's 1st funding round was a Series A of $52M, raised on Oct 2019.
Icosavax has 60 employees.
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
Icosavax's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Icosavax has 14 investors. Key investors include Astrazeneca, Citadel, Janus Henderson Investors, RA Capital, and Qiming Venture Partners.
Icosavax operates through Icosavax, Inc..
Yes. Icosavax was acquired by Astrazeneca in December 2023.